Pharmaceuticals News and Research

RSS

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Kolltan Pharmaceuticals, Inc., a next-generation oncology therapeutics company, announced today that it has raised $10 million in investments and related payments from an affiliate of Celtic Therapeutics Holdings L.P. (“Celtic Therapeutics”) and Tichenor Ventures, LLC.

20 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

Covidien announces results for first-quarter of fiscal 2010

Covidien plc today reported results for the first quarter of fiscal 2010 (October – December 2009). First-quarter net sales of $2.7 billion were up 7% from the $2.6 billion reported a year ago, with favorable foreign exchange of $121 million increasing the quarterly sales growth rate by approximately 5 percentage points.

20 Jan 2010

Varian announces the release of significant additions to its family of Pursuit LC columns

Varian, Inc. announced today the release of significant additions to its family of Pursuit™ LC (liquid chromatography) columns for pharmaceutical applications. New materials address needs from drug discovery to bioanalysis, saving time on analysis and method development.

20 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

New white paper examines how PCR mycoplasma tests and analysis save time and money

Contamination by mycoplasmal organisms is an ever-present concern in biopharmaceutical manufacturing. Their properties make them ready sources of contamination, while rendering them difficult and time-consuming to detect. A new free white paper, examines how PCR mycoplasma tests and analysis, deployed by a cutting-edge laboratory, minimizes testing delays and enable safe, high-volume biopharmaceutical production.

20 Jan 2010

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that AMRI’s high potency research laboratories and GMP-manufacturing facilities in Rensselaer, New York have met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and have been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

20 Jan 2010

Dr. Reddy’s Laboratories reports financial results for third-quarter ended December 31, 2009

Dr. Reddy’s Laboratories Ltd. today announced its unaudited financial results for the third quarter ended December 31, 2009 under International Financial Reporting Standards (IFRS).

20 Jan 2010

Over 44% of internet Viagra is counterfeit

Research by UK, Swedish and American researchers shows that taking internet drugs can kill and bypassing health systems can leave life-threatening problems undiagnosed. It's estimated that 90% of counterfeit drugs are sold on the internet, 44% of internet Viagra is fake, the global sale of counterfeit drugs will reach $75 billion this year and EU seizures have risen dramatically. Counterfeit drug deaths include men who took fake erectile dysfunction drugs, pregnant women injected with fake iron for anaemia and children who took paracetamol syrup contaminated with antifreeze.

20 Jan 2010

Telaprevir effective in HCV patients

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that data from recent clinical trials suggest that Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir is efficacious in hepatitis C virus patients who have not responded to previous treatment with peg-IFN/ribavirin. In contrast, the efficacy of Merck's (formerly Schering-Plough) boceprevir in treatment nonresponders has yet to be proven.

20 Jan 2010

Diamyd Medical executes share split

Diamyd Medical announces today that the company executes a 2:1 division of shares (i.e. a split), meaning that each share is divided into two shares of the same class.

20 Jan 2010

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia’s RNA Silencing: Mechanism, Biology and Application held January 14-19 in Keystone, Colorado.

20 Jan 2010

Teva Pharmaceutical Industries to donate over $7M in medicine to benefit earthquake victims in Haiti

Teva Pharmaceutical Industries Ltd. announced today that it will be donating over $7 million in medicine to benefit earthquake victims in Haiti. Teva is working with several of its Non-Governmental Organization (NGO) partners to ensure these drugs are delivered to Haiti without delay.

20 Jan 2010

Officials debate merits of medical marijuana as coping tool in pain fight

As access to medical marijuana becomes more widespread, officials are debating its use as a pain-coping treatment and are easing rules for the sick to use the drug, The Wall Street Journal reports. "The U.S. Department of Justice has said it will not generally prosecute ill people under doctors' care whose use of the drug complies with state rules. New Jersey will become the 14th state to allow therapeutic use of marijuana, and the number is likely to grow. Illinois and New York, among others, are considering new laws."

20 Jan 2010

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

20 Jan 2010

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

20 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

GEH, Exelon Generation agree to a landmark deal to deploy GEH’s isotope generation technology

Seeking to address a growing demand for the domestic and global supply of cobalt-60, a radioisotope used for treating cancer and other biomedical applications, GE Hitachi Nuclear Energy (GEH) and Exelon Generation Company have agreed to a landmark deal to deploy GEH’s isotope generation technology.

20 Jan 2010

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that U.S. gastroenterologists will treat a larger proportion of treatment nonresponder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe's telaprevir than Merck's boceprevir.

20 Jan 2010

Pharmaceuticals News and Research

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Covidien announces results for first-quarter of fiscal 2010

Varian announces the release of significant additions to its family of Pursuit LC columns

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New white paper examines how PCR mycoplasma tests and analysis save time and money

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Dr. Reddy’s Laboratories reports financial results for third-quarter ended December 31, 2009

Over 44% of internet Viagra is counterfeit

Telaprevir effective in HCV patients

Diamyd Medical executes share split

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

Teva Pharmaceutical Industries to donate over $7M in medicine to benefit earthquake victims in Haiti

Officials debate merits of medical marijuana as coping tool in pain fight

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Access Pharmaceuticals provides update on its Cobalamin insulin development program

GEH, Exelon Generation agree to a landmark deal to deploy GEH’s isotope generation technology

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence